Kymera Therapeutics (NASDAQ:KYMR) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.10, Zacks reports. The business had revenue of $22.10 million for the quarter, compared to analysts' expectations of $11.38 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business's quarterly revenue was up 114.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.69) EPS.

Kymera Therapeutics Trading Down 2.3 %

Shares of KYMR stock opened at $30.07 on Friday. Kymera Therapeutics has a twelve month low of $19.45 and a twelve month high of $53.27. The stock has a 50 day moving average of $29.57 and a 200 day moving average of $37.60. The stock has a market cap of $1.96 billion, a P/E ratio of -12.85 and a beta of 2.18.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 7,035 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the sale, the chief financial officer now directly owns 201,886 shares of the company's stock, valued at approximately $6,147,428.70. This trade represents a 3.37 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Jeremy G. Chadwick sold 1,383 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $42,112.35. Following the transaction, the chief operating officer now directly owns 67,800 shares of the company's stock, valued at approximately $2,064,510. The trade was a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,659 shares of company stock valued at $324,567 in the last 90 days. 15.82% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

KYMR has been the topic of a number of research analyst reports. HC Wainwright boosted their target price on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Stephens reaffirmed an "overweight" rating and set a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Finally, Citigroup started coverage on shares of Kymera Therapeutics in a report on Thursday, March 13th. They issued a "buy" rating and a $52.00 target price for the company. Three analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Kymera Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $56.36.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.